AMPEOTCdelisted

Ampio Pharmaceuticals, Inc.

Healthcare·Pain·Pre-clinical·Englewood, CO, United States
PainMusculoskeletal

Ampio Pharmaceuticals, Inc. (AMPE): 3 pipeline candidates. Updated within the last hour.

5.6/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health8.9

D/E 0.71 · 0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Ampio Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$208K

Cash

$4.1M

Quarterly Burn

Runway

Revenue

Pipeline (3 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

1

Total value held

$67

HolderSharesValue
cypress capital management llc (wy)440$67
·CEO: Mr. Michael A. Martino

Frequently asked questions

How many drug candidates are in Ampio Pharmaceuticals, Inc.'s pipeline?

Ampio Pharmaceuticals, Inc. (AMPE) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Ampio Pharmaceuticals, Inc.'s market capitalization?

Ampio Pharmaceuticals, Inc.'s market capitalization is approximately $208K.

Who is the CEO of Ampio Pharmaceuticals, Inc.?

Mr. Michael A. Martino is the chief executive officer of Ampio Pharmaceuticals, Inc. (AMPE).

Get the full picture on Ampio Pharmaceuticals, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.